Surgery Websites
Transplant Surgery »  Meet the Team »  Basic Scientists »  Qizhi Tang, Ph.D.
Qizhi Tang, Ph.D.

Qizhi Tang, Ph.D.

Professor of Surgery
Division of Transplant Surgery
Director, Transplantation Research Laboratory

Contact Information

(415) 476-1739
(415) 476-0789
(415) 502-8326 Fax
Qizhi.Tang@ucsf.edu

   
Open Popup

Peking Union Medical College, China, toward MD, 1984-89

University of South Alabama, toward PhD, Microbiology, 1989-91

University of Illinois at Chicago, Ph.D., Immunology, 1991-96

  • University of Illinois, Chicago, Postdoctoral Fellow, Immunology, 1996-98
  • University Of Chicago, Postdoctoral Fellow, Immunology, 1998-00
  • University of California, San Francisco, California, Postdoctoral Fellow, Immunology, 2000-02
  • Autoimmunity
  • Immune Tolerance
  • Immunotherapy
  • Islets of Langerhans Transplantation
  • Suppressor-Effector
  • T-Lymphocyte Subsets
  • T-Lymphocytes
  • Transplantation Immunology
  • Transplantation Tolerance

Dr. Tang attended Peking Union Medical College in China. After completing 5 years of the 8-year MD training, she left the program to pursue graduate education in the US and received her PhD in immunology from the University of Illinois at Chicago. She completed postdoctoral fellowships investigating mechanisms of immune tolerance at the University of Chicago and the University of California, San Francisco.

Dr. Tang joined the faculty at the University of California, San Francisco in 2002 as an Assistant Professor of Pathology in the Diabetes Center where she researched mechanisms of immune tolerance. She joined the Transplantation Division in the Department of Surgery in 2007 to lead basic research and translational research in transplant immunology. She has been the director of the UCSF Transplantation Research Laboratory since 2007 where she leads basic and translational research in transplantation.

A major research focus in the Tang Lab is on regulatory T cell therapy for autoimmune diseases and transplantation. Since 2011, she has also been co-directing the regulatory T cell therapy program at UCSF, which has supported 10 early-phase clinical trials in type 1 diabetes, pemphigus, islet transplantation, kidney transplantation and liver transplantation. Another area of research in the Tang Lab is on optimizing islet transplantation to enable highly efficient immunosuppression-free replacement of pancreatic beta cells for the treatment of type 1 diabetes.

Data provided by UCSF Profiles, powered by CTSI
ORCID iD: 0000-0001-7313-3574 Additional info
  • Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Diabetes in the Intra-Muscular Site: PARADIGM
    Sponsor:
    Sponsor ID:
    Funding Period:
    Jul 2019
    -
    Jun 2023
    Co-investigator
  • Islet transplant operational tolerance through minimization of ischemic injury and local immune regulation
    Sponsor:
    Sponsor ID:
    Funding Period:
    Sep 2019
    -
    Aug 2021
    PI
  • Novel Therapies to Modulate the Inflammatory Alloresponse in Renal Grafts
    Sponsor:
    Sponsor ID:
    Funding Period:
    Jul 2014
    -
    Jun 2021
    Co-investigator
  • Engineering Treg cells to treat type 1 diabetes
    Sponsor:
    Sponsor ID:
    Funding Period:
    Nov 2017
    -
    Oct 2020
    PI
  • Multiplex in situ gene expression and phenotypical profiling of inflamed tissues
    Sponsor:
    Sponsor ID:
    Funding Period:
    Jun 2015
    -
    May 2020
    Co-Principal Investigator
  • Diabetes Research Center
    Sponsor:
    Sponsor ID:
    Funding Period:
    Sep 2002
    -
    Mar 2020
    Co-Investigator
  • Promoting extrahepatic engraftment of human islets by parathyroid gland co-transplantation
    Sponsor:
    Sponsor ID:
    Funding Period:
    Jun 2018
    -
    May 2019
    PI
  • Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver Transplantation
    Sponsor:
    Sponsor ID:
    Funding Period:
    Jun 2014
    -
    May 2019
    Co-Principal Investigator
  • Regulatory 'T' Cell Control of Autoimmune Diabetes.
    Sponsor:
    Sponsor ID:
    Funding Period:
    Mar 2010
    -
    Feb 2016
    Principal Investigator
  • "Regulatory 'T'Cell Control of Autoimmune Diabetes".
    Sponsor:
    Sponsor ID:
    Funding Period:
    Mar 2010
    -
    Feb 2015
    Principal Investigator
  • "Donor-Specific Regulatory T Cell Therapy in Liver Transplantation"
    Sponsor:
    Sponsor ID:
    Funding Period:
    Apr 2012
    -
    Mar 2014
    Co-Principal Investigator
  • Donor-Specific Regulatory T Cell Therapy in Liver Transplantation
    Sponsor:
    Sponsor ID:
    Funding Period:
    Apr 2012
    -
    Mar 2014
    Co-Principal Investigator
  • BD FACS ARIA II CELL SORTER
    Sponsor:
    Sponsor ID:
    Funding Period:
    Feb 2010
    -
    Jan 2011
    Principal Investigator
  • Visualizing regulatory T cell control of autoimmunity
    Sponsor:
    Sponsor ID:
    Funding Period:
    Jul 2005
    -
    Jun 2008
    Principal Investigator
  • T CELL ACTIVATION AND ANERGY INDUCTION BY ANTI-CD3
    Sponsor:
    Sponsor ID:
    Funding Period:
    Feb 2000
    -
    Jan 0001
    Principal Investigator
Data provided by UCSF Profiles, powered by CTSI
MOST RECENT PUBLICATIONS FROM A TOTAL OF 106
Data provided by UCSF Profiles, powered by CTSI
  1. Tian W, Jiang SY, Jiang X, Tamosiuniene R, Kim D, Guan T, Arsalane S, Pasupneti S, Voelkel NF, Tang Q, Nicolls MR. The Role of Regulatory T Cells in Pulmonary Arterial Hypertension. Front Immunol. 2021; 12:684657. View in PubMed
  2. Parent AV, Faleo G, Chavez J, Saxton M, Berrios DI, Kerper NR, Tang Q, Hebrok M. Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection. Cell Rep. 2021 Aug 17; 36(7):109538. View in PubMed
  3. Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH, Liu W, Lares AP, Leinbach AS, Lee M, Nguyen V, Tamaki SJ, Tamaki W, Tamaki CM, Mehdizadeh M, Putnam AL, Spitzer MH, Ye CJ, Tang Q, Bluestone JA. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight. 2021 Sep 22; 6(18). View in PubMed
  4. Lee LM, Zhang H, Lee K, Liang H, Merleev A, Vincenti F, Maverakis E, Thomson AW, Tang Q. A Comparison of Ex Vivo Expanded Human Regulatory T Cells Using Allogeneic Stimulated B Cells or Monocyte-Derived Dendritic Cells. Front Immunol. 2021; 12:679675. View in PubMed
  5. Warshauer JT, Belk JA, Chan AY, Wang J, Gupta AR, Shi Q, Skartsis N, Peng Y, Phipps JD, Acenas D, Smith JA, Tamaki SJ, Tang Q, Gardner JM, Satpathy AT, Anderson MS. A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance. J Exp Med. 2021 Aug 02; 218(8). View in PubMed
  6. View All Publications

 

Site Directory
    X